Quince Therapeutics (NASDAQ:QNCX) Upgraded to Strong-Buy at Cantor Fitzgerald

Quince Therapeutics (NASDAQ:QNCX) was upgraded by equities researchers at Cantor Fitzgerald to a “strong-buy” rating in a research note issued to investors on Tuesday,Zacks.com reports.

Several other equities research analysts have also issued reports on QNCX. Wall Street Zen upgraded Quince Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, May 17th. Weiss Ratings downgraded Quince Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, May 1st. One analyst has rated the stock with a Strong Buy rating, five have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $44.67.

Quince Therapeutics Trading Up 4.4%

Shares of NASDAQ:QNCX opened at $0.97 on Tuesday. Quince Therapeutics has a 1 year low of $0.79 and a 1 year high of $45.50. The business has a fifty day simple moving average of $1.14 and a 200 day simple moving average of $10.53. The firm has a market cap of $15.78 million, a price-to-earnings ratio of -0.09 and a beta of 1.40.

Quince Therapeutics (NASDAQ:QNCX) last released its quarterly earnings data on Monday, May 11th. The company reported ($0.59) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.30) by $0.71.

Institutional Trading of Quince Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. XTX Topco Ltd acquired a new position in shares of Quince Therapeutics during the 2nd quarter valued at about $37,000. Intellectus Partners LLC acquired a new stake in Quince Therapeutics in the 4th quarter worth approximately $179,000. Hudson Bay Capital Management LP bought a new stake in Quince Therapeutics during the fourth quarter worth approximately $213,000. Quadrature Capital Ltd bought a new stake in Quince Therapeutics during the fourth quarter worth approximately $268,000. Finally, GSA Capital Partners LLP grew its holdings in Quince Therapeutics by 158.0% during the third quarter. GSA Capital Partners LLP now owns 87,235 shares of the company’s stock valued at $142,000 after purchasing an additional 53,417 shares during the last quarter. Institutional investors and hedge funds own 30.75% of the company’s stock.

About Quince Therapeutics

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions.